Why the study?
The effects of omega-3 polyunsaturated fatty acid supplementation for the primary prevention of clinical cardiovascular events in the general population have not been examined, and guidance is needed for various patient groups.
Does omega-3 polyunsaturated fatty acid supplementation prevent clinical cardiovascular events in patients with prevalent coronary heart disease, diabetes, or high cardiovascular risk?
Population
Patients with prevalent coronary heart disease, diabetes mellitus, prediabetes, high cardiovascular risk, stroke, heart failure, and atrial fibrillation
Comparison
Omega-3 polyunsaturated fatty acid supplementation versus no supplementation or placebo
Design
Review of large randomized controlled trials and scientific advisory
Authors
Loading...
Updates secondary prevention guidance for CHD, diabetes, and HF; extends prior AHA recommendations with cumulative RCT synthesis.
Does omega-3 polyunsaturated fatty acid supplementation prevent clinical cardiovascular events in patients with prevalent coronary heart disease, diabetes, or high cardiovascular risk?
This scientific advisory updates American Heart Association recommendations on the use of omega-3 fatty acid supplementation for the prevention of clinical cardiovascular events across various patient populations.
Siscovick et al. (2017) conducted a review in Clinical cardiovascular disease. Omega-3 polyunsaturated fatty acid (fish oil) supplementation was evaluated on Clinical cardiovascular events. This scientific advisory reviews large randomized controlled trials to update clinical recommendations for omega-3 polyunsaturated fatty acid supplementation to prevent cardiovascular events.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: